PAREXEL’s Head of BioPharm Unit Named to the 2016 PharmaVOICE 100
15 August 2016 - 11:00PM
Business Wire
PAREXEL International Corporation (NASDAQ: PRXL), a leading
global biopharmaceutical services provider, today announced that
PharmaVOICE magazine selected Ubavka DeNoble, MD, Corporate Vice
President, as one of the 100 most inspiring people in the life
sciences industry. The honor, published in the July/August 2016
issue of PharmaVOICE, recognizes Dr. DeNoble for her innovative
thinking, passion and fervor for the industry, and dedication to
mentoring the next generation of leaders.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20160815005033/en/
Ubavka DeNoble, MD, Corporate Vice
President, PAREXEL, named by PharmaVOICE as one of the 100 most
inspiring people in the life sciences industry. (Photo: Business
Wire)
At PAREXEL, Dr. DeNoble leads the Company’s BioPharm unit, a
dedicated team focused on the unique needs of small and mid-sized
biopharmaceutical companies. The BioPharm team collaborates with
clients to optimize processes associated with clinical trial
implementation, such as study start-up and patient recruitment, to
accelerate drug development for these companies.
“We are proud that Ubavka DeNoble is one of this year’s
PharmaVOICE 100,” said Josef von Rickenbach, Chairman and CEO,
PAREXEL. “Ubavka demonstrates her leadership, vision, and
dedication through her steadfast commitment to our employees and
our clients. Every day, she inspires those around her by
exemplifying PAREXEL’s High Performance Culture values, including
open communication, teamwork, innovation, and client service and
quality.”
The annual PharmaVOICE 100 list honors a select group of leaders
in the life sciences who positively impact their colleagues, peers,
organizations, and the industry at large. These individuals are
passionate, forward-thinkers who actively confront industry
challenges and trends. To read the 2016 PharmaVOICE profiles, visit
www.pharmavoice.com.
About PAREXEL InternationalPAREXEL International
Corporation is a leading global biopharmaceutical services company,
providing a broad range of expertise-based clinical research,
consulting, medical communications, and technology solutions and
services to the worldwide pharmaceutical, biotechnology and medical
device industries. Committed to providing solutions that expedite
time-to-market and peak-market penetration, PAREXEL has developed
significant expertise across the development and commercialization
continuum, from drug development and regulatory consulting to
clinical pharmacology, clinical trials management, and
reimbursement. PAREXEL Informatics provides advanced technology
solutions, including medical imaging, to facilitate the clinical
development process. Headquartered near Boston, Massachusetts,
PAREXEL has offices in 84 locations in 51 countries around the
world, and had approximately 18,600 employees in the fourth
quarter. For more information about PAREXEL International visit
www.PAREXEL.com.
PAREXEL and PAREXEL Informatics are trademarks or registered
trademarks of PAREXEL International Corporation or its affiliates.
All other trademarks are the property of their respective
owners.
This release contains “forward-looking” statements regarding
future results and events. For this purpose, any statements
contained herein that are not statements of historical fact may be
deemed forward-looking statements. Without limiting the foregoing,
the words “believes,” “anticipates,” “plans,” “expects,” “intends,”
“appears,” “estimates,” “projects,” “will,” “would,” “could,”
“should,” “targets,” and similar expressions are also intended to
identify forward-looking statements. The forward-looking statements
in this release involve a number of risks and uncertainties. Such
factors and others are discussed in the section entitled “Risk
Factors” of the Company’s most recent Annual Report on Form 10-K
and subsequent quarterly reports on Form 10-Q filed with the
Securities and Exchange Commission, which “Risk Factors” discussion
is incorporated by reference in this press release. The Company
specifically disclaims any obligation to update these
forward-looking statements in the future. These forward-looking
statements should not be relied upon as representing the Company’s
estimates or views as of any date subsequent to the date of this
press release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160815005033/en/
PAREXEL InternationalCristi Barnett, +1
781-434-4019Cristi.Barnett@PAREXEL.comorPAN CommunicationsJenny
Gardynski, +1 617-502-4300PAREXEL@pancomm.com
Parexel (NASDAQ:PRXL)
Historical Stock Chart
From Apr 2024 to May 2024
Parexel (NASDAQ:PRXL)
Historical Stock Chart
From May 2023 to May 2024